Matches in SemOpenAlex for { <https://semopenalex.org/work/W3106982672> ?p ?o ?g. }
- W3106982672 endingPage "106818" @default.
- W3106982672 startingPage "106818" @default.
- W3106982672 abstract "Rivaroxaban is a specific factor Xa (FXa) inhibitor for venous thromboembolism treatment. Recently, increasing evidence have reported the beneficial effects of rivaroxaban on treating cardiovascular disorders such as coronary and peripheral artery disease. However, its potential influence on abdominal aortic aneurysm (AAA) remains unclear. This study aims to investigate whether rivaroxaban treatment could attenuate experimental AAA progression and its related mechanisms. In human aneurysmal aorta, FXa protein expression was significantly upregulated. Further investigations identified a positive correlation among plasma FXa level, AAA severity (the maximal aortic diameter), and intra-aneurysmal thrombus percentage. In Ang II (angiotensin II)-infused ApoE −/− mice, the administration of high dose rivaroxaban (15 mg/kg/d) for 14 days significantly reduced the maximal aortic diameter, while low dose rivaroxaban (5 mg/kg/d) did not display such a protective role. Although rivaroxaban treatments reduced the incidence of AAA and thrombus formation, these differences did not reach statistical significance. Immunohistochemistry revealed a pronounced aortic remodeling including increased collagen content and enhanced elastin degradation in Ang II-induced AAAs, which was inhibited by high dose rivaroxaban treatment. Further analysis demonstrated that rivaroxaban exerted its protective effects by decreasing leukocyte infiltration, inflammatory cytokines expression, and matrix metalloproteinases (MMPs) expression in the aortic wall. The inhibitory effect of rivaroxaban on aneurysm development was also observed in calcium chloride-induced AAA model. Mechanistically, in human aortic endothelial cells, FXa stimulation increased the expression of inflammatory cytokines (interleukin (IL)-1β, IL-6, IL-8, monocyte chemoattractant protein-1) and adhesive molecules, which were all reversed by the cotreatment of rivaroxaban. Subsequent monocyte-endothelial cell interaction was enhanced after FXa stimulation and was alleviated by rivaroxaban cotreatment. In addition, FXa induced a significantly heightened expression of MMP2 in human aortic endothelial cells, which was ameliorated by rivaroxaban coadministration. Rivaroxaban attenuated both angiotensin II- and calcium chloride-induced abdominal aortic aneurysm (AAA) progressions, through inhibiting aortic remodeling and inflammation. Rivaroxaban could be a promising therapeutic agent in attenuating AAA development by counteracting FXa-induced aortic wall inflammation. • There was a positive correlation among factor Xa level, AAA severity, and intra-aneurysmal thrombus • Rivaroxaban treatment attenuated AAA progression in both angiotensin II- and Cacl 2 -induced AAA model • Rivaroxaban inhibited AAA progression by ameliorating aortic inflammation and aortic remodeling • Factor Xa increased the expression of inflammatory cytokines and adhesion molecules, which could be reversed by rivaroxaban" @default.
- W3106982672 created "2020-12-07" @default.
- W3106982672 creator A5009332911 @default.
- W3106982672 creator A5014407359 @default.
- W3106982672 creator A5042034500 @default.
- W3106982672 creator A5043370123 @default.
- W3106982672 creator A5052799796 @default.
- W3106982672 creator A5055132508 @default.
- W3106982672 creator A5055503093 @default.
- W3106982672 creator A5066068373 @default.
- W3106982672 date "2021-02-01" @default.
- W3106982672 modified "2023-10-18" @default.
- W3106982672 title "Factor Xa inhibitor rivaroxaban suppresses experimental abdominal aortic aneurysm progression via attenuating aortic inflammation" @default.
- W3106982672 cites W1947293078 @default.
- W3106982672 cites W1988167553 @default.
- W3106982672 cites W2013333624 @default.
- W3106982672 cites W2023229209 @default.
- W3106982672 cites W2037637421 @default.
- W3106982672 cites W2058370346 @default.
- W3106982672 cites W2087030893 @default.
- W3106982672 cites W2091918550 @default.
- W3106982672 cites W2109557274 @default.
- W3106982672 cites W2117677020 @default.
- W3106982672 cites W2132076028 @default.
- W3106982672 cites W2150179860 @default.
- W3106982672 cites W2277250099 @default.
- W3106982672 cites W2415651303 @default.
- W3106982672 cites W2519342050 @default.
- W3106982672 cites W2560156627 @default.
- W3106982672 cites W2590746963 @default.
- W3106982672 cites W2606821969 @default.
- W3106982672 cites W2738020565 @default.
- W3106982672 cites W2767407602 @default.
- W3106982672 cites W2771771060 @default.
- W3106982672 cites W2776247479 @default.
- W3106982672 cites W2780280329 @default.
- W3106982672 cites W2800530250 @default.
- W3106982672 cites W2902783010 @default.
- W3106982672 cites W2927894892 @default.
- W3106982672 cites W2995526000 @default.
- W3106982672 cites W3004407885 @default.
- W3106982672 cites W3011487043 @default.
- W3106982672 cites W3015539890 @default.
- W3106982672 cites W4229536675 @default.
- W3106982672 doi "https://doi.org/10.1016/j.vph.2020.106818" @default.
- W3106982672 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33227452" @default.
- W3106982672 hasPublicationYear "2021" @default.
- W3106982672 type Work @default.
- W3106982672 sameAs 3106982672 @default.
- W3106982672 citedByCount "18" @default.
- W3106982672 countsByYear W31069826722021 @default.
- W3106982672 countsByYear W31069826722022 @default.
- W3106982672 countsByYear W31069826722023 @default.
- W3106982672 crossrefType "journal-article" @default.
- W3106982672 hasAuthorship W3106982672A5009332911 @default.
- W3106982672 hasAuthorship W3106982672A5014407359 @default.
- W3106982672 hasAuthorship W3106982672A5042034500 @default.
- W3106982672 hasAuthorship W3106982672A5043370123 @default.
- W3106982672 hasAuthorship W3106982672A5052799796 @default.
- W3106982672 hasAuthorship W3106982672A5055132508 @default.
- W3106982672 hasAuthorship W3106982672A5055503093 @default.
- W3106982672 hasAuthorship W3106982672A5066068373 @default.
- W3106982672 hasConcept C126322002 @default.
- W3106982672 hasConcept C141071460 @default.
- W3106982672 hasConcept C2776098176 @default.
- W3106982672 hasConcept C2776301958 @default.
- W3106982672 hasConcept C2776914184 @default.
- W3106982672 hasConcept C2777323849 @default.
- W3106982672 hasConcept C2778661090 @default.
- W3106982672 hasConcept C2779161974 @default.
- W3106982672 hasConcept C2779980429 @default.
- W3106982672 hasConcept C2779993416 @default.
- W3106982672 hasConcept C2781362458 @default.
- W3106982672 hasConcept C71924100 @default.
- W3106982672 hasConcept C98274493 @default.
- W3106982672 hasConceptScore W3106982672C126322002 @default.
- W3106982672 hasConceptScore W3106982672C141071460 @default.
- W3106982672 hasConceptScore W3106982672C2776098176 @default.
- W3106982672 hasConceptScore W3106982672C2776301958 @default.
- W3106982672 hasConceptScore W3106982672C2776914184 @default.
- W3106982672 hasConceptScore W3106982672C2777323849 @default.
- W3106982672 hasConceptScore W3106982672C2778661090 @default.
- W3106982672 hasConceptScore W3106982672C2779161974 @default.
- W3106982672 hasConceptScore W3106982672C2779980429 @default.
- W3106982672 hasConceptScore W3106982672C2779993416 @default.
- W3106982672 hasConceptScore W3106982672C2781362458 @default.
- W3106982672 hasConceptScore W3106982672C71924100 @default.
- W3106982672 hasConceptScore W3106982672C98274493 @default.
- W3106982672 hasFunder F4320321001 @default.
- W3106982672 hasLocation W31069826721 @default.
- W3106982672 hasOpenAccess W3106982672 @default.
- W3106982672 hasPrimaryLocation W31069826721 @default.
- W3106982672 hasRelatedWork W1977067635 @default.
- W3106982672 hasRelatedWork W1993364384 @default.
- W3106982672 hasRelatedWork W2016821417 @default.
- W3106982672 hasRelatedWork W2074179446 @default.
- W3106982672 hasRelatedWork W2085364046 @default.
- W3106982672 hasRelatedWork W2346679716 @default.